In a significant move within the pharmaceutical industry, Novartis has entered into an agreement to launch a voluntary public takeover offer to acquire MorphoSys AG, a Germany-based global biopharmaceutical company renowned for developing innovative medicines in oncology. This acquisition, valued at EUR 2.7 billion, or EUR 68 per share, marks a strategic step for Novartis […]
Incyte (Nasdaq:INCY), an esteemed biopharmaceutical giant, has unveiled compelling expanded findings from its Phase 3 TRuE-AD3 study on the ruxolitinib cream (Opzelura) for treating children (aged ≥2 to <12 years) with atopic dermatitis (AD), the predominant form of eczema. These critical data points were spotlighted in an influential oral presentation at the European Academy of […]
Incyte has secured marketing authorization for Opzelura (ruxolitinib) cream 15mg/g from the European Commission (EC) for non-segmental vitiligo with facial involvement in adults and adolescents, aged 12 years and above. Opzelura is a cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib. It has been approved in the European Union (EU) to offer support for repigmentation […]
Opzelura FDA approval for vitiligo : Incyte has secured approval for Opzelura (ruxolitinib) cream 1.5% from the US Food and Drug Administration (FDA) for the topical treatment of nonsegmental vitiligo in adult and pediatric patients, aged 12 and older. Opzelura is a cream formulation of ruxolitinib, which selectively inhibits JAK1/JAK2. Opzelura FDA approval for vitiligo […]